Document is current
Any future updates will be listed below
-
Authors
Wynne, Chris
Wang, Bei
Deng, Rong
Li, Junyi
Eiger, Daniel
Bene Tchaleu, Fabiola
Heeson, Sarah
Restuccia, Eleonora
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche
- License Information
-
More Information
Article History
Received: 9 February 2025
Accepted: 9 May 2025
First Online: 14 June 2025
Declarations
:
: The study was done in conformance with Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was reviewed and approved by the institutional review board or ethics committee at each study site. All amendments affecting trial recruitment and conduct were approved.
: All subjects provided written, informed consent.
: SH is an employee of Roche Products Ltd and a shareholder of Roche stock; is a patent holder for PH FDC SC. JL, FBT and BW are employees of Genentech, Inc. and shareholders of Roche stock. RD is a paid consultant for Genentech, Inc. CW is a shareholder in New Zealand Clinical Research. DE was an employee of F. Hoffmann-La Roche Ltd (2020–2023) and owns Roche stock; was sponsored by Novartis for ESMO Fellowship (2018–2019); and is currently employed by Bristol Myers Squibb. ER is an employee of F. Hoffmann-La Roche Ltd and a shareholder of Roche stock.
